- Home
- ISRL vs LCTX Comparison
ISRL vs LCTX Comparison
Compare ISRL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- LCTX
- Stock Information
- Founded
- ISRL 2021
- LCTX 1990
- Country
- ISRL United States
- LCTX United States
- Employees
- ISRL N/A
- LCTX N/A
- Industry
- ISRL Blank Checks
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISRL Finance
- LCTX Health Care
- Exchange
- ISRL Nasdaq
- LCTX Nasdaq
- Market Cap
- ISRL 144.2M
- LCTX 166.3M
- IPO Year
- ISRL 2023
- LCTX N/A
- Fundamental
- Price
- ISRL $11.25
- LCTX $0.86
- Analyst Decision
- ISRL
- LCTX Strong Buy
- Analyst Count
- ISRL 0
- LCTX 3
- Target Price
- ISRL N/A
- LCTX $5.67
- AVG Volume (30 Days)
- ISRL 13.4K
- LCTX 446.6K
- Earning Date
- ISRL 01-01-0001
- LCTX 11-14-2024
- Dividend Yield
- ISRL N/A
- LCTX N/A
- EPS Growth
- ISRL N/A
- LCTX N/A
- EPS
- ISRL N/A
- LCTX N/A
- Revenue
- ISRL N/A
- LCTX $8,719,000.00
- Revenue This Year
- ISRL N/A
- LCTX N/A
- Revenue Next Year
- ISRL N/A
- LCTX $123.52
- P/E Ratio
- ISRL $37.45
- LCTX N/A
- Revenue Growth
- ISRL N/A
- LCTX N/A
- 52 Week Low
- ISRL $10.61
- LCTX $0.77
- 52 Week High
- ISRL $11.27
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- ISRL 58.26
- LCTX 46.44
- Support Level
- ISRL $11.24
- LCTX $0.88
- Resistance Level
- ISRL $11.26
- LCTX $0.97
- Average True Range (ATR)
- ISRL 0.01
- LCTX 0.05
- MACD
- ISRL -0.00
- LCTX 0.00
- Stochastic Oscillator
- ISRL 59.18
- LCTX 37.10
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.